1 / 68

Case Study 2: Symptomatic Bradycardia

Case Study 2: Symptomatic Bradycardia. Robert S. Hoffman, MD Director New York City Poison Center. Objectives. Understand the differential diagnosis of drug-induced bradycardia Explain the use of the laboratory in cases of unknown bradycardia

karl
Download Presentation

Case Study 2: Symptomatic Bradycardia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Case Study 2: Symptomatic Bradycardia Robert S. Hoffman, MD Director New York City Poison Center

  2. Objectives • Understand the differential diagnosis of drug-induced bradycardia • Explain the use of the laboratory in cases of unknown bradycardia • Discuss the treatment of patients with known and unknown causes of bradycardia

  3. Differential Diagnosis • A 42 year old man presents to the hospital complaining of weakness and dizziness following an intentional drug overdose • He is pale and diaphoretic appearing but awake • Blood pressure 62/30 mm Hg • Pulse 40/minute; slightly irregular • Physical examination otherwise normal

  4. ECG

  5. EAPCCT Investigation of the Poisoned Patient-Case Studies Bordeaux, May 2010

  6. Question 1 • The most likely etiology of this patient’s toxicity is: • A. Digoxin • B. Calcium channel blocker • C. Beta blocker • D. Clonidine • E. Organophosphate

  7. Answer 1 • You can not be certain at this point: • A. Digoxin • B. Calcium channel blocker • C. Beta blocker • D. Clonidine • Sedation • E. Organophosphate • Muscarinic and nicotinic findings

  8. Physiology

  9. Physiology

  10. Physiology

  11. Physiology

  12. Beta Blocker

  13. Digoxin Toxicity

  14. EAPCCT Investigation of the Poisoned Patient-Case Studies Bordeaux, May 2010

  15. Question 2 • Which laboratory tests might be useful to help narrow the differential diagnosis • A. Glucose • B. Calcium • C. Potassium • D. Sodium • E. Both A and C

  16. Answer 2 • Which laboratory tests might be useful to help narrow the differential diagnosis • A. Glucose • B. Calcium • C. Potassium • D. Sodium • E. Both A and C

  17. Diagnosis and Prognosis Bismuth C, et al: Clin Toxicol 1973; 6:153-162

  18. Composite endpoints • Death • Vasoactive drugs (epinephrine, etc) • Pacemaker

  19. 22.2 mmol/L

  20. EAPCCT Investigation of the Poisoned Patient-Case Studies Bordeaux, May 2010

  21. Question 3 • Which ECG finding is MOST characteristic of digoxin toxicity: • A. Scooped ST segment • B. Sinus bradycardia • C. Atrial tachycardia with high degree A-V block • D. Bidirectional ventricular tachycardia • E. Slow atrial fibrillation

  22. Digoxin Effect

  23. Bradycardia

  24. Atrial Tachycardia with A-V Block

  25. More

  26. Bidirectional Ventricular Tachycardia

  27. Answer 3 • Which ECG finding is MOST characteristic of digoxin toxicity: • A. Scooped ST segment • B. Sinus bradycardia • C. Atrial tachycardia with high degree A-V block • D. Bidirectional ventricular tachycardia • E. Slow atrial fibrillation

  28. EAPCCT Investigation of the Poisoned Patient-Case Studies Bordeaux, May 2010

  29. Question 4 • Which rhythm is inconsistent with digoxin toxicity • A. Sinus tachycardia • B. Rapid atrial fibrillation • C. Supraventricular tachycardia at 150/min • D. Multifocal atrial tachycardia • E. All of the above

  30. Answer 4 • Which rhythm is inconsistent with digoxin toxicity • A. Sinus tachycardia • B. Rapid atrial fibrillation • C. Supraventricular tachycardia at 150/min • D. Multifocal atrial tachycardia • E. All of the above

  31. More Case Information • ECG: As shown previously • Glucose: 300 mg/dL (16.16 mmol/L) • Serum potassium: 4.8 mmol/L • A fluid bolus of 1L of saline is given without response • Blood pressure 72/40 mm Hg • Pulse 45/min

  32. EAPCCT Investigation of the Poisoned Patient-Case Studies Bordeaux, May 2010

  33. Question 5 • Which of the following therapies is most appropriate at this point? • A. Digoxin antibodies • B. Epinephrine • C. Glucagon • D. Calcium • E. Milrinone

  34. General Treatment

  35. Answer 5 • Which of the following therapies is most appropriate at this point? • A. Digoxin antibodies • B. Epinephrine • C. Glucagon • D. Calcium • E. Milrinone

  36. Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM: Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther 1993;267:744-50

  37. More Case Information • A serum digoxin concentration is reported as non-detectable. • The patient is given the following with little improvement: • 3 grams of calcium chloride • Escalating doses of glucagon (up to 10 mg) • Amrinone • Dopamine continuous infusion

  38. EAPCCT Investigation of the Poisoned Patient-Case Studies Bordeaux, May 2010

  39. Question 6 • Which therapies might be indicated next: • A. Hemodialysis/hemoperfusion • B. Pacemaker • C. Intra-aortic balloon pump • D. High-dose insulin euglycemia therapy • E. Intravenous fat emulsion

  40. Answer 6 • Which therapies might be indicated next: • A. Hemodialysis/hemoperfusion • B. Pacemaker • C. Intra-aortic balloon pump • D. High-dose insulin euglycemia therapy • E. Intravenous fat emulsion

  41. Cardiac Energy Dynamics • Normal Function • Preferred Substrate • Fatty Acids • High energy • Stable pool

  42. Cardiac Energy Dynamics • Sick hearts • Convert to glucose • Immediate energy • Limited availability • Large swings • Basis for: • Tight glucose control • High dose insulin/euglycemia therapy

  43. Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM: Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther 1993;267:744-50

  44. Kline JA, et al. Cardiovasc Res 1997;34:289-298

  45. Yuan TH, et al: Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol 1999;37:463-474

  46. Technique • Bolus 1 unit/kg of regular insulin • Follow with a continuous infusion • 0.5-2.0 units/kg/hour of regular insulin • Add glucose as necessary • 0.5-1 gm/kg/hr • Allow mild hypokalemia (only mild)

  47. Lipid Emulsion Therapy • Mechanism of action • 2 Prevailing hypotheses • “Lipid sink theory” • Bioenergetic theory

  48. Lipid Emulsion Therapy • Lipid sink theory • Intralipid partitions the drug into a lipid phase creating a concentration gradient for removal of the drug from the target organ Weinberg GL: Reg Anesth Pain. 2006;31:296

  49. Tebutt S: Intralipid prolongs survival in a rat model of verapamil toxicity. Acad Emerg Med 2006;13:134

More Related